Literature DB >> 11054568

Puromycin resistance (pac) gene as a selectable marker in vaccinia virus.

J M Sánchez-Puig1, R Blasco.   

Abstract

The antibiotic puromycin, an inhibitor of protein synthesis, was shown to inhibit vaccinia virus (VV) replication. We evaluated the use of puromycin-resistance (pac) gene as a selectable marker in VV. A recombinant vaccinia virus expressing pac (VV-pac) under the control of a viral early/late promoter was constructed and characterized. VV-pac grew in the presence of puromycin at concentrations that were inhibitory for the parental VV and toxic for the cells. Isolation of recombinant VV usually relies on plaque purification under selective conditions. Because virus plaquing was not feasible under inhibitory puromycin concentration, a protocol based on serial passage of virus was devised. The usefulness of this procedure in selecting pac expressing viruses was tested by isolating a recombinant VV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11054568     DOI: 10.1016/s0378-1119(00)00398-x

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

1.  Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins.

Authors:  Beatriz Perdiguero; Rafael Blasco
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Use of a negative selectable marker for rapid selection of recombinant vaccinia virus.

Authors:  Stacy D White; Kip Conwell; Jeffrey O Langland; Bertram L Jacobs
Journal:  Biotechniques       Date:  2011-05       Impact factor: 1.993

3.  Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Authors:  David A Garber; Leigh A O'Mara; Jun Zhao; Sailaja Gangadhara; InChul An; Mark B Feinberg
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

4.  A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.

Authors:  Ali Alejo; Margarida Saraiva; Maria Begoña Ruiz-Argüello; Abel Viejo-Borbolla; Mar Fernández de Marco; Francisco Javier Salguero; Antonio Alcami
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.